abstract |
The present invention provides compositions and methods for adoptive cell therapy comprising modified immune cells that express an antigen-targeting chimeric antigen receptor and a prodrug-converting enzyme for the treatment of inflammation, inflammatory diseases, and or pathogenic infections. |